Advertisement

Interleukin-10 as a Potential Immunosuppressor in Patients with Human Immunodeficiency Virus and Its Modulation After the First Cycle of Autovaccination Treatment

  • P. Pradeaux
  • E. M. Schneider
  • B. Harms
  • H. T. Brüster
Conference paper

Abstract

Lymphocytes from HIV-infected patients before and after the first cycle of AUVA treatment were tested for their cytokine release pattern. Patients with more than 200 CD4+ cells/µl responded with increased or constant levels of interleukin (IL)-10 but decreased levels of tumor necrosis factor (TNF) alpha after in vitro stimulation with 10% AUVA material. These patients responded with increased or constant levels of CD4+ cells during the first course of treatment. Patients with less than 200 CD4+ cells never showed a positive IL-10 response but presented with reduced TNF alpha production in vitro if positive levels had been detected before. These data are consistent with the interpretation that AUVA directly downmodulates TNF alpha production by increased production of IL-10 and/or by the action of activated transforming growth factor (TGF)-β in vitro. The results can explain stimulation and increase of CD4+ TH2 type cells in patients entering the treatment protocol with more than 200 CD4+ cells as well as the direct clinical improvement by suppressing inflammatory events in vivo.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Steel CM, Beatson D, Cuthbert RJG, Morrison H, Ludlam CA, Peutherer JF, Simmonds P, Jones M (1988) HLA haplotype A1 B8 DR3 as a risk factor for HIV related disease. Lancet i:l185–1188CrossRefGoogle Scholar
  2. 2.
    Kaslow RA, Duquesnoy R, van Raden M, Kingley L, Marrari M, Friedman H, Su S, Saah AJ, Detels R, Phair J, Rinaldo C (1990) A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. Lancet 335: 927–930PubMedCrossRefGoogle Scholar
  3. 3.
    Hashimoto S, Michalski JP, Berman MA, McCombs C (1990) Mechanism of a lymphocyte abnormality associated with HLA-B8/DR3: role of interleukin 1. Clin Exp Immunol 79: 227–232PubMedCrossRefGoogle Scholar
  4. 4.
    Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LBA, Duff GW (1993) An allelic polymorphism within the human tumor necrosis factor alpha promotor region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177: 557–560PubMedCrossRefGoogle Scholar
  5. 5.
    Riddell SR, Gilbert MJ, Greenberg PD (1993) CD 8+ cytotoxic T cell therapy of cytomegalovirus and HIV infection. Curr Oppinion Immunol 5: 484–491CrossRefGoogle Scholar
  6. 6.
    Birx DL, Redfield RR (1993) Immunotherapeutic strategies in the treatment of HIV infection and AIDS. Curr Opinion Immunol 5: 600–607CrossRefGoogle Scholar
  7. 7.
    Atla H, Gersten MJ, Salk PL, Salk J (1993) Can AIDS be prevented by T-cell vaccination. Immunol Today 14: 200–202CrossRefGoogle Scholar
  8. 8.
    Brüster HT, Holder A, Illes A, Kuntz BME, Lehnert E, Molling R, Scheja JW, Schneider M (1993) Langzeitstudie einer Therapie mittels lymphozytärer Autovakzine bei HIV-infizierten Patienten. In: Scharrer I, Schramm W (eds) 23. Hämophilie-Symposium, Hamburg 1992. Springer, Berlin Heidelberg New York, pp 68–73Google Scholar
  9. 9.
    Del Prete G, de Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S (1993) Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150: 353–360PubMedGoogle Scholar
  10. 10.
    Pecanha LMT, Snapper CM, Lees A, Yamaguchi H, Mond JJ (1993) IL-10 inhibits T cell independent but not T cell-dependent responses in vitro. J Immunol 150: 3215 - 3223PubMedGoogle Scholar
  11. 11.
    Bogdan C, Palk J, Vodovotz Y, Nathan C (1992) Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-ß and interleukin 10. J Biol Chem 267: 23301–23308PubMedGoogle Scholar
  12. 12.
    Gerard C, Bruyns C, Marchant A, Abramowicz D, Vadenabeele P, Delvaux A, Fiers W, Goldman M, Velu T (1993) Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177: 547–550PubMedCrossRefGoogle Scholar
  13. 13.
    Chen W-F, Zlotnik A (1991) IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 147: 528–534PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • P. Pradeaux
  • E. M. Schneider
  • B. Harms
  • H. T. Brüster

There are no affiliations available

Personalised recommendations